Picture of Hookipa Pharma logo

HOOK — Hookipa Pharma News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapTurnaround

Hookipa Pharma Inc Expected To Post A Loss Of 10 Cents A Share: Earnings Preview

* HOOKIPA Pharma Inc  HOOK.OQ   HOOK.O  is expected to show
a fall
in quarterly revenue when it reports  results on May 9 for the
period ending March 31 2024
    * The New York City-based  company is expected to report a
11.8% decrease in revenue to $2.8 million from $3.18 million a
year ago, according to the mean estimate from 3 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for HOOKIPA Pharma Inc is
for a
loss of 10 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for HOOKIPA
Pharma
Inc is $4.50​, above​ its last closing price of $0.88. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.20       -0.19      -0.22     Missed  -14
 Sep. 30 2023  -0.23       -0.21      -0.17     Beat    19
 Jun. 30 2023  -0.19       -0.21      -0.22     Missed  -5.3​
 Mar. 31 2023  -0.22       -0.23      -0.27     Missed  -19.5
 ​​Dec.        -0.18       -0.21      -0.17     Beat    20.9
 31 2022                                                
 Sep. 30 2022  -0.29       -0.28      -0.25     Beat    11.2​
 Jun. 30 2022  -0.36       -0.36      -0.23     Beat    36.1
 Mar. 31 2022  -0.24       -0.24      -0.40     Missed  -66.7
 This summary was machine generated May 7 at 16:38 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Hookipa Pharma

See all news